Eli Lilly and Company (NYSE:LLY) Shares Sold by Imprint Wealth LLC

Imprint Wealth LLC lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 49.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 1,375 shares of the company’s stock after selling 1,349 shares during the quarter. Imprint Wealth LLC’s holdings in Eli Lilly and Company were worth $808,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the company. JGP Wealth Management LLC lifted its position in Eli Lilly and Company by 0.9% during the 4th quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock worth $1,074,000 after acquiring an additional 16 shares in the last quarter. Cassia Capital Partners LLC grew its holdings in Eli Lilly and Company by 1.8% during the 3rd quarter. Cassia Capital Partners LLC now owns 951 shares of the company’s stock valued at $511,000 after purchasing an additional 17 shares in the last quarter. Walkner Condon Financial Advisors LLC increased its stake in Eli Lilly and Company by 2.8% during the 3rd quarter. Walkner Condon Financial Advisors LLC now owns 621 shares of the company’s stock worth $334,000 after buying an additional 17 shares during the period. Patton Albertson Miller Group LLC lifted its holdings in Eli Lilly and Company by 2.8% in the 3rd quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company’s stock worth $335,000 after buying an additional 17 shares in the last quarter. Finally, Valley Wealth Managers Inc. grew its stake in shares of Eli Lilly and Company by 1.3% during the third quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock valued at $688,000 after acquiring an additional 17 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded down $4.68 during mid-day trading on Tuesday, reaching $746.09. 852,929 shares of the company traded hands, compared to its average volume of 3,062,083. Eli Lilly and Company has a fifty-two week low of $367.35 and a fifty-two week high of $800.78. The firm has a market cap of $708.90 billion, a PE ratio of 128.77, a price-to-earnings-growth ratio of 1.65 and a beta of 0.34. The stock has a fifty day simple moving average of $762.68 and a 200-day simple moving average of $655.54. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.19. The company had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same period last year, the firm earned $2.09 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 12.46 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on LLY shares. Barclays increased their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research note on Wednesday, February 7th. JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a report on Friday, March 15th. Morgan Stanley lifted their target price on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research report on Friday, February 16th. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Finally, BMO Capital Markets lifted their price objective on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a report on Wednesday, February 7th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $728.05.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the transaction, the insider now owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.